Search Results

article GPCR Publication Highlights βCGRP breaks the mold: Distinct signaling patterns reveal it’s more than

EuroscreenFast EuroscreenFast has been a pioneer in GPCR science for more than 30 years,. Today, their catalogue includes over 1,000 functional assays representing more than 550 GPCR and other

For biotech founders, this is more than a presentation problem. It’s a strategic vulnerability. academic interest to practical significance. 3️⃣ Why it’s different ✅ Differentiation must be more than who you’re building for, why now is the right time, and how your solution fits into something bigger than

.” — Tom Sakmar This makes them more than biomarkers — they’re potential drivers of disease .

. 👉 The problem begins when ambition grows faster than structure. This is where the structural tension begins. 👉 Scientific optionality grows faster than strategic capacity And this is where biotech fundraising begins to feel harder than it should.

As JB puts it, the cost of not asking is much higher than the cost of momentary discomfort. This mindset shapes careers far more than publications alone.

DiscoverX Partnership — Tools and Insight for GPCR Drug Discovery Modern GPCR discovery depends on more than DiscoverX , a global provider of GPCR assay platforms and translational biology services covering more than

science well, but not the value capture From an investor's perspective, this creates confusion rather than 👉 IP discussions happen earlier in fundraising conversations 👉 Investors look for alignment rather than Biotech fundraising will favor teams that use intellectual property as a tool for clarity rather than

becomes unclear 👉 Capital allocation appears fragmented 👉 The development timeline looks crowded rather than And uncertainty, even when the science is strong, slows biotech fundraising more than most founders expect Saying yes often feels safer than saying no.

Timeline slips are absorbed as “part of biology” rather than examined as managerial signals. start planning around delays BD and investor messaging drifts Timelines become aspirational rather than

. 👉 How long can we operate if fundraising takes longer than expected? visibility fades while the company keeps moving forward , until choices are driven by urgency rather than That shift creates space to act deliberately again, rather than being pushed forward by circumstances

Most GPCR programs don’t fail because of weak molecules—they fail because biology behaves differently than Translate potency and efficacy realistically  → Recognize when deviations reflect biology rather than

By visualizing enzymes as dynamic molecular partners rather than static filters, drug discovery scientists Cytochrome P450: Friend, Foe, and FDA Focus No enzyme class is more important—or more unpredictable—than Yet many discovery teams still relegate them to the “ADME” checklist, rather than the strategic design

The analog AOP-RANTES also internalizes CCR5, but drives the receptor toward degradation rather than And judicious tag placement on endosomal markers, rather than the receptor itself, allows detection of

Recent studies showed that some AVPR2 mutations could cause biased Gαq/11 protein coupling rather than R68W showed bias to coupling with Gαq/11 protein rather than V162A and wild-type receptor.

obvious mistakes , and why preventing that drift requires a different kind of leadership awareness than Founders often sense this as friction rather than failure. Meetings feel heavier. organizationally. 👉 By the time leadership recognizes the gap, correcting course requires far more effort than

The science evolves, assumptions break, and timelines shift quietly rather than dramatically. The discovery phase stretches longer than planned. The right ones also know when progress matters more than perfection. 👉 These signals are subtle, but

reporting the % of displacement measured at 1 µ M and the corresponding Ki for those showing a % higher than across all concentrations, indicating that reduced tracer signal was due to receptor occupancy rather than validation in intact cells, the approach provides a richer picture of ligand–receptor interactions than

GPCR is much more than a podcast? Come check out the brand new Dr.

The suppressive rather than activating effects of pGRP were confined to blood flow at a high shear rate Blockage of PTK2 or interference of CIB1 no more than slightly affected thrombus formation at a low shear

designed as a continuous learning environment — supporting scientific reasoning as programs mature, rather than Misinterpretation does more than delay progress.

More than a technical overview, this is a story of curiosity, persistence, and using science to meet Rather than being discouraged by challenges, he views them as forcing functions for creativity and growth

Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical

Here, the Schild plot becomes a diagnostic tool  rather than a checkbox test: Slopes >1  often mean incomplete to Partial Agonists Partial agonists complicate things—they activate receptors but less effectively than

grows, it becomes a searchable extension of Terry’s teaching — designed for repeated exposure rather than

The move comes less than three weeks after X4 pulled together a $55 million PIPE and amended a loan facility

This time with none other than Dr. Bryan Roth There are 10 open tickets available. Get yours now!

GPCR Podcast, we have none other than Dr. Marta Filizola!

Our guest is none other than Dr. Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.

determine partner preference; or (iii) the dynamics of GPCR binding to different types of partners rather than